• BioExec Institute
• Modules
• Faculty
• Participants
• Registration
• Logistics
• Cleantech Exec
• Industry events

Martin Babler is the Chief Executive Officer of Principia Biopharma, a healthcare start-up established to develop novel drugs for cancer and immune diseases. Prior to joining Principia, Mr. Babler was CEO of Talima Therapeutics, Inc., a privately-held drug delivery company. He has also held a variety of roles of increasing responsibility in sales, sales management, marketing and business development with Immunology Sales and Marketing, Genentech, Inc, and Eli Lilly and Company. Mr. Babler holds a degree in Pharmacy/Pharmacology from the Swiss Federal Institute of Technology in Zurich, Switzerland and attended the Executive Development Program at Kellogg Graduate School of Management.

Dr. Black is a Professor in the Department of Microbiology, Immunology, and Molecular Genetics at the University of California, Los Angeles, and the David Geffen School of Medicine at UCLA. His B.A. degree is in chemistry from the University of California, Santa Cruz. He received his Ph.D. degree in molecular biochemistry and biophysics at Yale University, working with Joan Steitz. Prior to his appointment at UCLA, he worked with David Baltimore and Donald Rio at the Whitehead Institute for Biomedical Research as a Helen Hay Whitney and American Cancer Society fellow. He was also a fellow of the David and Lucile Packard Foundation.

Chris Boerner joined Seattle Genetics in December 2010. He has broad experience in oncology product marketing, including pre-launch planning and on-market commercialization. Prior to Seattle Genetics, Dr. Boerner spent more than eight years at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including Director of Marketing on Avastin and Director of Avastin franchise management. Additionally, he served in a variety of marketing roles across multiple disease areas, including immunology and lymphoma. Dr. Boerner joined Genentech from McKinsey & Company, a global strategic management consulting firm. He most recently was Vice President of Marketing at Dendreon. Dr. Boerner received his Ph.D. and M.A. in Business Administration from the Haas School of Business at the University of California, Berkeley, and holds an A.B. in Economics and History from Washington University in St. Louis.

Casper is a 20 year veteran of the medical device and life sciences industry. He brings extensive operating experience to NVP having led marketing and commercialization efforts for cardiovascular device, specialty pharmaceutical and diagnostic companies. Based in NVP's Palo Alto office, Casper focuses on mid to late stage investments in medical devices, specialty pharmaceuticals and healthcare services. Therapeutic products that address a critical unmet medical need, that are "less" traumatic or have a defined path to regulatory approval are of particular interest. His current board seats include Basis and Simpirica Spine. Prior to NVP, Casper was a Partner at U.S. Venture Partners (USVP) in Menlo Park, where he invested in therapeutic companies from clinical development through commercialization. At USVP, Casper served as a Board member for AtheroMed, Ilypsa (acquired by Amgen) and Valeritas. Over a six year period he was actively involved in making and managing investments in more than a dozen companies as a member of the healthcare team. Casper was also a private investor and board member with Innospine, an orthopedic diagnostic company acquired by Kyphon in 2005. Previously, Casper spent four years as Vice President of Business Development, Sales and Marketing at Aerogen, a specialty pharmaceutical company developing inhaled therapeutics for diabetes and respiratory diseases (public company acquired by Nektar then Novartis). In 1999 he co-founded and venture funded Epicor to develop a market leading epicardial ablation treatment for atrial fibrillation (acquired by St. Jude Medical for over $200M in 2004). Prior to Epicor, Casper held senior marketing positions at Heartport (acquired by Johnson and Johnson) and Diagnostic Products Corporation (acquired by Siemens). At Heartport, Casper launched an integrated surgical product line to perform minimally invasive cardiovascular surgery. Previously at Diagnostics Products Corporation, he managed a portfolio of oncology, infectious disease and infertility immunoassay tests which doubled to $105M in revenues during his tenure. At these companies, Casper worked closely with the engineering, scientific and clinical teams in product development, coordinated multiple U.S. product launches and had ongoing responsibility for managing international distribution. Earlier in his career, Casper worked internationally for three years as a strategy consultant for Bain & Company. Casper holds an M.B.A. from Stanford University Graduate School of Business, an M.S. in Biological Science from Stanford University and a B.A. in Biochemistry from Dartmouth College.

Keith has over 30 years serving the Life Sciences and Health Care industry in a variety of capacities. He leads the industry practice for Deloitte on the West Coast and serves on the firm's National Life Sciences Management committee. In his capacity he overseas the Deloitte services provided to virtually all of its West Coast biotech and pharmaceutical clients, regardless of the nature of those services. In addition, to his leadership role he also serves as the lead partner serving some of the firm's largest clients in the biotech industry. As a senior partner for Deloitte, Keith has assisted many public companies, international clients and early-stage companies with mergers & acquisitions, IPO services, regulatory matters, capital financing and strategic and operational matters. He has also assisted numerous companies with Sarbanes-Oxley Section 404 readiness and attestation engagements.

He is an active member of a variety of industry associations including BIO, BayBio, Biocom and CHI. Keith is also a member of the Board of Directors for BayBio. He participated in the 2005 UC Berkeley BioExec Institute. He is a frequent speaker and presenter for industry matters at Deloitte presented programs. He is a CPA and a 1975 graduate of the University of Wisconsin - Eau Claire.

Dr. Donabedian is the Vice President of Strategic Alliances in GSK's Centre of Excellence for External Drug Discovery (ceedd). In his role, Dr. Donabedian is primarily responsible for identifying and evaluating new business opportunities for the U.S. ceedd. Prior to joining the ceedd, Dr. Donabedian served as a principal of his own consultancy practice providing business development services to emerging biotechnology companies. He has sourced and closed several agreements with biopharmaceutical companies and academic institutions. Dr. Donabedian also serves as the Treasurer of the Healthy Lifespan Institute, a non-profit organization dedicated to extending healthy lifespan through studying, educating, and testing the rapid advances in the science and medicine of aging. Dr. Donabedian’s previous senior level positions include CEO, COO and VP of Business Development for Tutorzilla, BioChemics, and Surface Logix. Dr. Donabedian also worked as a Sr. Manager in Accenture’s Strategic Services Consulting Group serving both in the U.S. and internationally, with assignments focusing on R&D post-merger integration, business unit strategy, and resource planning. Prior to Accenture, Dr. Donabedian held senior level positions at Sentry® Products, a Union Carbide life science venture (now Dow Chemical), where he headed a product development team specializing in developing and patenting a broad range of technologies to the life sciences industries. Dr. Donabedian began his research career as a scientist with SciMed Life Systems, a division of Boston Scientific, where he developed novel bioadhesives to treat abdominal aortic aneurysms. Dr. Donabedian is an inventor/co-inventor on several patents and has published several papers in peer-reviewed journals in the field of polymer science. Since 2006, Dr. Donabedian has served as a member of University of Massachusetts Lowell Plastics Advisory Committee. He is also as an Alumni Network Advisor for the University of North Carolina Business School. Dr. Donabedian served as a Mentor for the Durham Scholars program and was invited as a guest lecturer at the University of Indiana’s Kelly School of Business and University of North Carolina’s Business School. He received an A.B. from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell and an M.B.A. from the University of North Carolina Chapel Hill where he was a Deloitte Case Cup Challenge Winner.

Mark Edwards Mark has over 25 years of experience in the life sciences industry. Mark was the founder of Recombinant Capital and has an extensive track record advising biotech and pharmaceutical companies with alliance strategies, negotiation, and execution.

Coming soon.

Dr. Abhay Joshi is the President, CEO and Director of Alvine Pharmaceuticals, Inc. He has over eighteen years of global operations and research and development experience in biologic, pharmaceutical and medical device industries in the United States, Europe, Latin America and Asia Pacific. Prior to Alvine, Dr. Joshi served as an Executive Vice President, Chief Technical Officer and member of Executive Committee at CoTherix, Inc., now Actelion Ltd. Dr Joshi held various senior management positions at Allergan. He was the Vice President of Global Technical Operations, Specialty Pharmaceuticals at Allergan where he was responsible for the company's global biologics manufacturing operations for BOTOX® and its Latin America and Asia Pacific pharmaceutical operations. Dr. Joshi received his BTech in Chemical Engineering from the Indian Institute of Technology, New Delhi, an MSE and a Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, and an MBA from the University of California, Irvine. Dr. Joshi holds an adjunct faculty appointment at the University of Southern California School of Pharmaceutical Sciences.

You have to believe Karl Handelsman is fully immersed in science when the Managing Director of CMEA’s Life Sciences division listed solar astronomy and synthetic biology as his favorite pastimes. The 11-year CMEA veteran has a passion for science and innovation . Karl has been privileged to work alongside talented entrepreneurs. The management teams at Ambrx, Ensemble Discovery, Ilypsa, Intellikine, Kalypsys, Maxygen, Phenomix, Rigel, Syrrx, Tetraphase, and Xenoport – all have contributed to Karl’s wealth of experience executing visionary plans. Prior to joining CMEA, Karl worked in biotech business development at Millennium. He was one of the first employees of Tularik, and the Whitehead Institute.

Ms. Heller is Executive Vice President of Business Development at Exelixis and has more than 15 years of legal and business development experience in the pharmaceutical and biotech industries. Prior to joining Exelixis, Ms Heller was Head of Strategic Alliances at Novartis Pharmaceuticals where she was responsible for transactions with partners in the pharmaceutical and biotech industry as well as academic institutions worldwide. Prior to joining Novartis, Ms. Heller was Vice President, Corporate Development and Legal Affairs at Signature BioScience, Inc. a drug discovery company focused in oncology. Previously, she was Corporate and Intellectual Property Counsel for Celera Genomics, where she was the head of the legal department and responsible for negotiating corporate and business transactions and collaborations. She has also held several positions of increasing responsibility in the areas of business development, licensing, and sales & marketing.

Ms. Heller is a member of the California State Bar, is licensed by the US Patent and Trademark Office and has a B.S. in biology from Tulane University an M.A. in biology from American University and J.D. from Golden Gate University School of Law.

Dana Hughes is a Senior Director in Pfizer’s Worldwide Strategy and Innovation team. Last year, he led the integration of the Wyeth human pharmaceutical business and now has been ensuring successful implementation across the enterprise. He has also been involved in enterprise projects in corporate strategy, innovative deal structures and the new Worldwide Research & Development organization. Additionally, he has done work for the human drug business in adherence, distribution and the pain therapeutic area. Prior to Pfizer, Dana was a Principal in the New York office of The Boston Consulting Group. His work was focused on strategy and financial performance of healthcare and information technology clients. Earlier, Mr. Hughes advised market-leading multi-industry businesses with Lazard Freres & Co. He was also a Senior Associate at the former CSC Index. Mr. Hughes has an AB cum laude in Classical Archaeology from Harvard College and an MBA in international finance from Columbia Business School. He lives in Brooklyn, NY.

David A. Kessler, MD, was until recently the dean and vice chancellor for medical affairs at UCSF School of Medicine. Before joining UCSF in the fall of 2003, Dr. Kessler had been Dean of the Yale University School of Medicine since July 1997. Dr. Kessler, who served as Commissioner of the United States Food and Drug Administration from November 1990 until March 1997, was appointed by President Bush and reappointed by President Clinton.

As commissioner of the FDA, he acted to speed approval of new drugs and placed high priority on getting promising therapies for serious and life-threatening diseases to patients as quickly as possible. He introduced changes in the device approval process to make it more efficient and ensure that it meets high standards. Under his direction, the FDA announced a number of new programs, including: the regulation of the marketing and sale of tobacco products to children; nutrition labeling for food; user fees for drugs and biologics; preventive controls to improve food safety; measures to strengthen the nation's blood supply; and the MEDWatch program for reporting adverse events and product problems. He emphasized strong law enforcement and created an Office of Criminal Investigation within the agency. According to The New York Times (11/27/96), David Kessler " revitalized a beleaguered agency that had become mired in bureaucratic disarray." The Los Angeles Times (11/27/96) praised him for " restor[ing] the Food and Drug Administration to what it was meant to be - an aggressive advocate for the public's health." With his departure, "[t]he American people lost one of their most effective champions" (New York Daily News, 11/28/96).

Dr. Kessler has a wide range of experience in research, clinical medicine, education, administration, and the law. He is a 1973 magna cum laude, Phi Beta Kappa graduate of Amherst College. He received his J.D. degree from The University of Chicago Law School, where he was a member of the Law Review, in 1978, and his M.D. degree from Harvard Medical School in 1979. He did his internship and residency in pediatrics at the Johns Hopkins Hospital. In 1986, he earned an Advanced Professional Certificate from the New York University Graduate School of Business Administration.

Brian McRee is currently the Director of Sales & Operations planning for the North American Region for the Roche/Genentech network. Brian's responsibility include collaboration with the Commercial organization and the international manufacturing network to ensure that supply and demand are effectively balanced and that key supply chain metrics are achieved. Brian has worked for Genentech for the past eight years, most recently with responsibility for the operational planning of the overall Genentech manufacturing network. Brian's background is primarily in finance. He has served as a financial director at Genentech, supporting the manufacturing organization including the CMO organization, Process development and manufacturing strategic planning during a time of incredible growth. Past experiences also have included 8 years at Silicon Graphics, in a variety of roles including Finance Director of the America's Region, (including sales and order management responsibilities) and Brian also served at a Silicon Graphics facility in Switzerland in the position of manufacturing controller and was responsible for leading a variety of supply chain optimization initiatives from a financial standpoint. Brian also has held positions at Unisys and Charles Schwab & Co. Brian is a UC Berkeley Haas School of Business Graduate, Class of 1983 and also has a Master's in Business from Cal State Hayward.

Mr. Munos is the founder and chief apostle of InnoThink, a partnership dedicated to bringing evidence-based innovation models to the pharmaceutical industry and its stakeholders. Before that, he was advisor for corporate strategy at Eli Lilly and Company, where he focused on disruptive innovation and the radical redesign of the industry R&D model. His research, which has been published in Nature and Science, has helped stimulate a broad rethinking of the pharmaceutical business model by companies, investors, policymakers, regulators, and patient advocates.

He has presented his findings at numerous meetings sponsored by the National Academies, the Institute of Medicine, the President's Cancer Panel, the NIH Leadership Forum, the World Health Organization, the OECD, the Kauffman Foundation, the U.S. Patent and Trademark Office, Genome Canada, the American Chemical Society, and the Council for American Medical Innovation as well as leading universities and think-tanks in the U.S. and Europe.

He received his MBA from Stanford University and holds other graduate degrees in economics and animal science from the University of California at Davis and the Institut National Agronomique in Paris, France.

"What I do: InnoThink was created to advance research into breakthrough innovation, and help bring new evidence-based innovation models to the pharmaceutical industry and its stakeholders. It rests on work I started during my 30-year career at Eli Lilly, which led to a series of publications in Nature and Science that have helped stimulate a broad rethinking of the pharmaceutical business model by the industry, investors, policy-makers, regulators, and patient advocates.

I have presented my findings at meetings sponsored by the National Academies, the Institute of Medicine, the OECD, the President's Cancer Panel, The NIH Leadership Forum, the World Health Organization, the Kauffman Foundation, FasterCures, the US Patent and Trademark Office, Genome Canada, the American Chemical Society, The Council for American Medical Innovation, the Genetic Alliance, as well as leading universities and think-tanks in the US and Europe.

Projects

Our understanding of breakthrough innovation has dramatically improved in the last 10 years. However, these insights have not translated into better innovation models, and unsupported assumptions about what causes innovation remain common across the industry.

InnoThink's objective is to help correct this by bringing new evidence-based innovation models to the pharmaceutical Industry and its stakeholders"

Kristin Peck is Executive Vice President, Worldwide Business Development and Innovation for Pfizer Inc. and a member of Pfizer's Executive Leadership Team. In this role, Ms. Peck is responsible for Pfizer's merger and acquisition, licensing, venture capital, alliance management and innovative business model activities.

In her Business Development role over the last year, Ms. Peck has overseen the completion of numerous deals, including ones involving King Pharmaceuticals, FoldRx, Biocon and Teuto. She also led the team that launched a first-of-its-kind, enterprise-wide, web-based platform focused on innovation to harness the creative energies and insights of Pfizer colleagues to drive continued growth at Pfizer.

Ms. Peck joined Pfizer in 2004 in a Strategy role, and later became Senior Vice President of Worldwide Strategy and Innovation. Ms. Peck's Strategy team led the development of Pfizer's current strategies and global operating model review process. With Pfizer's acquisition of Wyeth in 2009, she led the global integration, focusing on ensuring the combined companies successfully delivered the promised value for patients, customers, shareholders and other stakeholders. She subsequently took on responsibility for Business Development, becoming Senior Vice President, Worldwide Business Development, Strategy and Innovation.

Prior to joining Pfizer, Ms. Peck was a principal with the Boston Consulting Group (BCG), focusing on strategy and merger-related issues in the pharmaceutical and financial services industries. Before BCG, Ms. Peck worked in private equity and real estate finance at Prudential, The O'Connor Group and J.P. Morgan. Ms. Peck holds a bachelor's degree from Georgetown University and an M.B.A. from Columbia Business School. Ms. Peck and her husband live in Connecticut with their two children and dogs.

Stephanie Robertson is currently the Director of Industry Alliance and Program Management for the University of California, San Francisco. In this role her group oversees the on-going industry partnerships at the University including Pfizer and Sanofi-Aventis and works team members in the Office of Technology, Innovation and Industry Partnerships to develop innovative alliances with industry and UCSF.

Since joining UCSF in 2009, Dr. Robertson has served in various leadership roles including Program Director for the Sandler Center for Drug Discovery, where she continues to oversee drug discovery programs targeting therapeutics for neglected third world parasitic diseases. She also managed the overall program for the Multiple Myeloma Translational Initiative at UCSF.

Prior to joining UCSF, Dr. Robertson worked for 10 years at Exelixis, Inc. During her tenure at Exelixis the company grew from tiny start-up to over 700 employees. Her most recent position of Associate Director of R&D held responsibilities that included project management for early phase clinical programs and alliance management for several collaborations with large pharma. In addition, she served as a scientific project leader for several drug discovery programs in cancer, cardiovascular disease and metabolism. She earned an undergraduate degree in chemistry (Honors) at the University of Michigan, Ann Arbor, and a Ph.D. in chemistry at the University of California, Berkeley.

Barbara Ryan is a Managing Director at Deutsche Bank Securities Inc., and joined the firm (formerly Alex Brown & Sons), in April 1992 as a senior analyst covering the Large Cap U.S. Pharmaceutical Industry. Barbara has been covering the US Pharma sector for 25 years (since 1982), and while at Alex Brown, also covered the PBM industry, healthcare distributors, as well as the drug wholesalers, and some specialty pharma companies. In 2005, she extended her coverage to include the U.S. drug distributors. Barbara has been recognized by the Wall Street Journal All-Star Analyst survey, and is a four-time member of the Institutional Investor All-America Research Team Prior to joining Deutsche Bank, Barbara was a senior analyst at Prudential Securities, for two years, and began her sell-side career at Bear Stearns, in 1981. Barbara studied at the University of Massachusetts, and majored in Finance. Barbara lives with her husband, Al Filippone, and their two sons in Connecticut, and participates in USTA league tennis competition.

James is the Vice President of Genentech Partnering. Prior to this, he was President and CEO of Arete Therapeutics as well as Chairman of the Board of Directors and former CEO of Cytokinetics, a company he co-founded in August 1997. He currently sits on Cytokinetics' scientific advisory board. Prior to Cytokinetics, he held faculty positions at the University of California, San Francisco and Harvard Medical School. He serves on the Board of Directors of HopeLab, a not-for-profit organization developing innovative technologies for the management of cancer, obesity and other diseases. He is a former member of Dean’s Council of the Kennedy School of Government at Harvard University and serves on the advisory board of the California Institute of Quantitative Biosciences. He received an M.D. from Queen’s University and a Ph.D. in Neuroscience from the University of California, San Francisco. His continued interests are in identifying,completing and managing drug discovery and development alliances that focus on novel targets and approaches to managing serious medical illness. In particular, he is interested in approaches that take into consideration the complexity and variation inherent in the human biological processes and putting the drug discovery process in an evolutionary context.

Patrick J. Scannon, M.D., Ph.D. is XOMA's Company Founder, Executive Vice President, Chief Medical Officer and a member of the Board of Directors of XOMA Ltd. Since 1980, Dr. Scannon has directed the Company's product identification, evaluation and clinical testing programs. As Chief Medical Officer, he heads the clinical research programs and has evaluated several classes of biologic compounds and conducting clinical studies for infectious, oncologic and immunologic indications. Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and a medical degree from the Medical College of Georgia. He completed his medical internship and residency in internal medicine at the Letterman Army Medical Center in San Francisco. A board-certified internist, Dr. Scannon is also a member of the American College of Physicians. He is the inventor or co-inventor of several issued U.S. patents, and has published numerous scientific abstracts and papers. Dr. Scannon has served as a Trustee of the University of California Berkeley Foundation and as a member of the University of California Berkeley Chancellor's Community Advisory Board. He has served or is serving on the boards of several companies and institutions, and is currently a member of the National Biodefense Science Board (NBSB), a federal advisory board for the Department of Health and Human Services and a member of the Defense Sciences Research Council (DSRC), a research board for Defense Advanced Research Projects Agency (DARPA).

Dr. Schmatz has over 30 years of drug discovery and development experience in pharmaceutical research. Most recently he was Vice President of Basic and Preclinical Research for Merck Research Laboratories in Japan where he was the Site Head for a research facility with over 400 researchers focused on Oncology and Metabolic Disorders. Previous to this role he was Vice President of Merck Basic Research in Rahway NJ where he was responsible for Human and Animal Infectious Disease Research and Immunology. During his 30 year career at Merck Dr. Schmatz has managed research teams across diverse therapeutic areas toward the successful delivery of pipeline compounds. Significant contributions include the discovery of; new biochemical pathways and drug targets, novel natural products with antimicrobial activity, and several approved drugs including CANCIDAS, an antifungal agent for treating serious life threatening hospital infections and INVANZ, an IV carbapenam antibiotic for treating bacterial infections. He has also served on, and chaired, a number of scientific committees for the World Health Organization. He is currently a member of the Board of Directors and Chairman of the External Scientific Advisory Committee for the Medicines for Malaria Venture in Geneva which is focused on developing new chemotherapeutic agents for treating malaria in the developing world. Dr. Schmatz has extensive experience in establishing research collaborations and developing licensing opportunities on an international level. He received his PhD in Biochemistry/Cell Biology from Rutgers University in 1984.

David Summa is currently the Chief Business Advisor of Acumen Pharmaceuticals, a pre-clinical drug development company that is developing the first effective therapeutics and diagnostics that prevent Alzheimer's disease.

Prior to joining Acumen, Dave was the President and CEO of Mendel Biotechnology, a successful genomics company that was the first to functionally characterize all the transcription factors in arabidopsis thaliana. Mendel's traits now form the core of the Monsanto product pipeline.

Before joining the ranks of Bay Area biotech entrepreneurs, Dave was a Vice President at Monsanto where he created Renessen, the joint venture between Cargill and Monsanto.

Prior to joining Monsanto, Dave was a partner at McKinsey & Company, Inc. where he was the global leader of the Innovation Practice. Dave received his BS and MS from MIT in the department of Chemical Engineering.

Bill Taranto joins Merck as Managing Director, Global Health Innovation Fund LLC and Executive Director, Global Health Innovation Group (GHI). Bill will be responsible for building the GHI capability for Merck. His job responsibilities will be to work across the Strategy Office, other Divisional and employee groups, and with external input to scout out new business opportunities outside traditional pharmaceutical and vaccine projects. Bill will work to build early concepts and drive business plan development for these opportunities and work on early incubation of new opportunities. Additionally, Bill will be a member of the Innovative Ventures Board, a group that manages the identification and funding of a portfolio of emerging businesses. Bill will also sit on the leadership team with the Strategy Development Group, Strategy Realization Office, and Enterprise Wide Portfolio Management leaders to ensure the sharing of information and networking across the Strategy Office.

Prior to joining Merck, Bill spent 18 years at Johnson & Johnson in various marketing, sales and business development roles with increasing responsibility. In his previous position, Executive Director, Health Care Strategy & Alliances, Bill was responsible for evaluating the future healthcare environment, the viability and impact of health care channels, and the creation of new health care business models. Bill started his career as a sales representative for Janssen Pharmaceutica and progressed through various sales and marketing positions, including an assignment in Beerse, Belgium. Prior to joining J&J, Bill spent eight years in investment banking. Bill has a Bachelor of Business Administration from St. Bonaventure University.

Mr. Thompson is a co-founder of Proteus. He is also a Managing Member of Spring Ridge Ventures, and has led the incubation of Proteus since inception. From 1994-1999, Mr. Thompson co-founded and served as a director and chief executive officer of FemRx until the company was acquired by Johnson & Johnson. Previously, Mr. Thompson co-founded and was chief financial officer for CardioRhythm through its acquisition by Medtronic. He holds an M.A. in engineering from Cambridge University, where he was a United Kingdom National Engineering Scholar, an M.A. in education from Stanford University and a M.B.A. from Stanford University Graduate School of Business.

Dr Topper joined Frazier Healthcare in 2003 as a Venture Partner and became a General Partner in 2005. Since joining Frazier Healthcare, Dr. Topper has led multiple biopharma investments. Dr Topper led Frazier Healthcare's investment in Calistoga Pharmaceuticals that was acquired by Gilead in April 2011 for an up-front payment of $375 million, Alnara Pharmaceuticals that was acquired by Eli Lilly for initial consideration of $190 million and Cotherix (Nasdaq CTRX) that was acquired by Actelion for $420 million. Dr. Topper currently serves on the boards of Amicus Therapeutics (Nasdaq FOLD), Incline Therapeutics, Silence Therapeutics, and Anaptys Biosciences.

Prior to joining Frazier Healthcare, he served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Prior to the merger of COR and Millennium, Dr. Topper served as the Vice President of Biology at COR and was responsible for managing all of its research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR, where he functioned as a clinician, instructor and basic investigator.

Dr. Topper received his M.D. and Ph.D. (in Biophysics) from Stanford University School of Medicine in 1991 under the auspices of the Medical Scientist Training Program. He completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston and is board certified in both disciplines. After completing a research fellowship in the Vascular Research Division in the department of Pathology at the Brigham and Women's hospital, he joined the faculty of Harvard Medical School from 1997 to 1998, and subsequently Stanford University as an Assistant Professor of Medicine (Cardiovascular) in July 1998. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. He continues to hold an appointment as a Clinical Assistant Professor of Medicine at Stanford University and as a Cardiology Consultant to the Palo Alto Veterans Administration Hospital.

Dr. Turner joined Merck Research Laboratories in 1985. Since then he has held many positions of increasing seniority at the company. In 1999 he was appointed Senior Vice President, Merck Frosst Centre for Therapeutic Research in Montreal, Canada. In 2002 he returned from Montreal to take up his current position as Senior Vice President, Worldwide Licensing and External Research. Dr. Turner oversees all of Merck's licensing activities and the management of academic relations. Through his multiple and diverse experiences in the Merck Research Laboratories, he has acquired a broad perspective on drug discovery and development. During Merv's tenure in Licensing, there has been a sizeable increase in deal activity for Merck, with over 230 significant transactions completed since 2003. Under Dr. Turner's leadership, Merck has also been active in mergers and acquisitions with companies such as Aton, Abmaxis, GlycoFi, Sirna and NovaCardia. Dr. Turner sees partnerships and M & A as a logical product of the cultural shift within Merck towards a more outward-facing and partner-friendly organization. Dr. Turner has authored over 80 articles in peer reviewed journals and has served on the editorial boards of many of them. Dr. Turner trained as a chemist at the University of Sheffield in the UK. After completing postdoctoral research at Harvard University, he returned to the UK and pursued an academic career in molecular parasitology until joining Merck in 1985.

Mr. Tong works with his clients to understand how economic, financial, and reimbursement forces can be managed and how to influence product acceptance and utilization. His consulting engagements focus on strategic planning and implementation in early phases of product development, during clinical evaluation, and following regulatory approval. Mr. Tong has worked across a number of different clinical specialties and therapeutic categories including: hematology and oncology; solid organ and bone marrow transplantation; infectious diseases like HIV/AIDS and hepatitis; cardiovascular diagnostics and therapeutics; dermatology; orthopedic surgery; and anesthesiology/pain medicine.

Mr. Tong is an active member of numerous professional organizations and societies including: the Academy of Managed Care Pharmacy; American Public Health Association; American Society for Blood and Marrow Transplantation; American Society of Clinical Oncology; Infectious Disease Society of America; International Society for Heart and Lung Transplantation; International Society for Pharmacoeconomics and Outcomes Research; and Society for Investigative Dermatology.

Prior to founding Quorum Consulting, Mr. Tong was a senior associate with Corning HTA (now known as Covance), a Washington, DC health care consulting firm. Prior to entering the consulting field, Mr. Tong was active in clinical and health services research at the University of California at Los Angeles Neuropsychiatric Institute and the University of Pennsylvania Department of Medicine. He holds a MS Business and Management, Johns Hopkins University and a BA, University of Pennsylvania

Dr. Wiebe is Founder and President of Quantum Consulting based in Redwood City, California. His consulting practice is focused on biotechnology development, biosafety, manufacturing, quality assurance and GMP compliance. He has 24 years of experience in the CMC aspects of biotechnology and has participated as a member of numerous product development teams that were successful in bringing new biotech products through the development pipeline and into commercial life. He has held positions at the following companies: Genentech, 1984-1998 (Senior Scientist, Cell Culture Development; Sr. Director, Quality Control); BioReliance, 1998-2001 (Chief Scientific Officer and Vice President of Quality & Regulatory Affairs); IDEC Pharmaceuticals, 2001-2003 (Vice President of Quality); Biogen Idec, 2003-2005 (Vice President of Corporate Quality & Drug Compliance); Novartis (formerly Chiron), 2005-2007 (Vice President of Quality Assurance for U.S. Biopharmaceutical Operations). Earlier in his career Dr. Wiebe held positions at Duke University Medical School (Research Fellow), Cornell University Medical College (Assistant & Associate Professor), and the New York Blood Center (Associate Investigator). He received his Ph.D. in Microbiology from the University of Kansas and his B.S. in Natural Sciences from Sterling College (Kansas).

Mr. Weingarten was appointed as Director of the NCI SBIR & STTR Small Business Programs in 2005. In that role, he is overseeing the development of new strategies to optimize the impact of this Program in advancing emerging technologies towards clinical development and commercialization. Mr. Weingarten served from 1990 until 2005 at NASA Headquarters in Washington, D.C. Most recently, he held the position of Program Manager, Exploration Systems Research and Technology Program at NASA, where he led a team of scientific and technical experts focused on the biomedical industry and the public health application of emerging technologies, as well as leading collaborative teams in building partnerships with private and public sector organizations to address public health needs. Earlier, as Program Manager of NASA’s Innovative Partnerships Program, he oversaw the Partnership Development Programs and Small Business Programs, formulating national policy and providing leadership on the development and implementation of educational outreach campaigns targeted towards small businesses. Mr. Weingarten also served as a Program Analyst from 1989 to 1990 at the Department of State. He holds a Masters in Political Science from Columbia University.

Gregg Alton is Senior Vice President and General Counsel for Gilead Sciences, Inc. Mr. Alton joined Gilead in 1999 and is currently responsible for legal affairs, government affairs and health policy and Gilead's access program. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward LLP where he focused on mergers and acquisitions, corporate partnership and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the board and treasurer of the AIDS Healthcare Foundation. He received his J.D. from Stanford Law School and his bachelor's degree from the University of California at Berkeley.

Mr. Anthony most recently was chief executive officer at Pharmix Corp., a San Francisco-based computational design drug company. Prior to Pharmix, Mr. Anthony was responsible for creating many successful in-licensing and out- licensing partnerships, as senior vice president of business development at Saegis Pharmaceuticals, now part of Lundbeck of Denmark. Mr. Anthony also was senior vice president of business development at Tularik, where he played an instrumental role in the acquisition of Tularik by Amgen in 2004. Mr. Anthony has served in senior business development and marketing positions at such innovative biotechnology firms as FibroGen, Cell Therapeutics, and Inhale (now Nektar) Therapeutics, negotiating research, development and commercialization deals with numerous universities, and global biotechnology and pharmaceutical companies. Mr. Anthony began his career in life sciences with Baxter Healthcare Corporation, where he spent more than 15 years, ultimately serving as a vice president of Baxter's Blood Therapy Group. He earned a Bachelor of Science degree in biology from Allegheny College.

Martin Babler was until recently VP of Immunology Sales and Marketing at Genentech with responsibility for Xolair, Rituxan Immunology and the late stage Immunology pipeline.

Prior to this, Martin was Senior Director and head of Commercial Development in charge of marketing and strategic input for all products in Genentech's pipeline across the different therapeutic areas. His team was focused on creating high value assets in close collaboration with Research and Development and introduced several new tools and systems to the organization that help optimize product launches.

Martin joined Genentech several years ago as Director of Marketing in the Cardiovascular Franchise.

Prior to joining Genentech, Martin held various roles of increasing responsibility in sales, sales management, marketing and business development on a global as well as affiliate level with Eli Lilly and Company.

Martin Babler holds a degree in Pharmacy/Pharmacology from the ETH in Zurich, Switzerland and has attended the Executive Development Program at Kellogg Graduate School of Management.

Chris Boerner is currently a Group Product Marketing Manager for Xolair covering promotions. In this role Chris manages a team responsible for all direct to physician and patient promotional activities for Xolair, including physician marketing, direct to patient programs, advocacy group activities and conventions / medical meeting programs. Prior to this role, Chris was responsible for strategy development for Xolair. In addition to his role on Xolair, Chris has worked in Genentech's Market Development Group. Most recently he was Associate Director of Oncology Market Planning. In this role, Chris managed teams responsible for all commercial analytics for Genentech's in-line and pipeline oncology products.

Prior to joining Genentech, Chris worked at McKinsey & Company. He is Graduate of the Business and Public Policy Ph.D. Program at the Hass School of Business at UC Berkeley, where specialized in Economics. His dissertation focused on firm strategy in the pharmaceutical industry.

• Over 22 years of pharmaceutical sales and marketing experience
• Led two oncology product launches in the US
• Oversaw three product line extension launches in Europe and Japan
• Led a phase III clinical development team in Europe
• Sits on the global Oncology and Infection Therapy Area Team as the commercial leader
• Currently responsible for strategic commercial view on internal and external projects impacting the AstraZeneca Oncology and Infection portfolio

Felissa Cagan joined Jazz Pharmaceuticals as its Vice President, Intellectual Property in March 2004. Prior to joining Jazz, she was Senior Director, Intellectual Property, at Nektar Therapeutics (formerly Inhale Therapeutic Systems) beginning in March 1997. Ms. Cagan was patent counsel at ALZA Corporation from 1994 to 1997. Prior to joining ALZA, she was an associate with the law firm of Morrison & Foerster. Ms. Cagan received her J.D. from the Santa Clara University School of Law and a B.S. in Chemical Engineering from Northwestern University. She is a registered Professional Engineer in the State of California and was a practicing Chemical Engineer for seven years prior to attending law school.

Joseph A. Carlino, Ph.D. is an independent biopharmaceutical project management consultant with over 30 years of experience in biomedical and pharmaceutical R&D, including over 20 years in project management within the biopharmaceutical industry. He received his Ph.D. in Pathobiology/Immunology from Columbia University and worked at institutions including Memorial Sloan-Kettering Cancer Center, Cetus Corporation, Celtrix Pharmaceuticals, and Chiron Corporation. His clients include a spectrum of small-to-medium sized biotech companies where he leads project teams, manages corporate partners, drives project decisions, defines and implements team and committee structures, and writes development plans. Joe is an active speaker on drug development and project management, and he contributes to the management of project management and drug development professional associations in Northern California, including Project Managers in Pharmaceuticals (www.projmgr.org) and BioScience Forum (www.biosf.org).

Dr. Chen is part of a distinguished group at Burrill consisting of professionals who are called upon to use their extensive academic training and international background to harness the vast potential in the biotech industry. In his professional career, Dr. Chen has made numerous contributions in assessing technology, transferring discoveries into the clinic, raising venture investment and establishing strategic partnerships among pharmaceutical and biotech companies. Dr. Chen's current merchant banking activities are spread out worldwide and include relationships in Australia, Canada, China, and the United Kingdom. Previously Dr. Chen built talented scientific teams in immunology, genomics, virology, gene therapy and cell biology at Roche Diagnostics, Sentinel Biosciences, Progenesys, and SyStemix (a Novartis company). He played a key role in the IPO of the first biotech start-up that he joined, as well as the acquisition of SyStemix and Sentinel Biosciences by Novartis and Roche Diagnostics. Dr. Chen studied at the University of Wisconsin-Madison and Stanford University.

Grace Colon joined Gilead Sciences in 2005 as Senior Director, Commercial Strategy. In that role, she was responsible for supporting global franchise planning and analysis, including market research, competitive intelligence and financial modeling and forecasting, and new therapeutic area product planning. Currently, she is Senior Director, Corporate Strategy, and is responsible for implementing a new Alliance Management function.

Previously, she was VP of Corporate Planning at Affymetrix where she was responsible for strategic planning, business intelligence, and project management. Prior to Affymetrix, Grace was with McKinsey & Co. where she served clients in health care, high tech and venture capital.

She was also Acting COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Grace holds a BS degree in chemical engineering from the University of Pennsylvania and a Ph.D. in chemical and biochemical engineering from the Massachusetts Institute of Technology. She also was a postdoc at MIT in the Department of Biology. She has written numerous peer-reviewed scientific and business publications, been an invited speaker at a number of conferences and has licensed two industrial biotechnology inventions.

She is a member of the Board of the Professional Women's Healthcare Alliance and serves on the Outstanding Corporate Innovator Selection Committee of the Product Development and Management Association.

Dr Cooper is a Principal of Deloitte Consulting and is the National Leader of the Life Sciences R&D practice. She has two decades of experience working in various capacities relating to the pharmaceutical industry. For the past 13 years she has worked as a consultant to the industry. Prior to joining Deloitte Consulting she was a partner in the Global Pharmaceutical/Life Sciences Practice within IBM Business Consulting practices, where she had responsibility for leading the Global R&D Pharmaceutical/Life Sciences Practice. In her current client relationship role there she has responsibility for product and service offerings in research and development to selected global pharmaceutical companies headquartered in the U.S.

In her career as a consultant Dr. Cooper has participated in a broad range of strategic advisory services for pharmaceutical companies. Activities included creating global business models; supporting the integration of development, regulatory, and drug safety functions in a number of pharmaceutical mergers; restructuring global marketing while facilitating a product launch; restructuring regulatory affairs; reengineering the regulatory and clinical components of a product development process; and reengineering information management processes.

Prior to becoming a consultant, Dr. Cooper worked for eight years within the pharmaceutical industry. Her background spanned clinical development, regulatory affairs, sales, and marketing. She gained a broad range of experience in developing new products and obtaining product licenses in the UK and the U.S. She also contributed to the launching of a major new pharmaceutical brand while also maintaining the growth of older existing products in competitive therapeutic markets while she was with Janssen Pharmaceutical Ltd.

Dr. Cooper is a frequent participant at industry conferences where she frequently speaks on topics relating to the issues affecting pharmaceutical research and development. She holds a Joint Honours Bachelor of Science Degree in Chemistry and Pharmacology and a PhD in Pharmacology from the University of London, UK.

Fred Craves, PhD, is an Investment Partner, Managing Director and Founder of Bay City Capital, and serves as a member of the board of directors and Chairman of the executive committee. Before founding Bay City Capital, he spent over 20 years leading and managing biotechnology and pharmaceutical companies. Previously, he was Executive Vice President of Schering Berlin and Chief Executive Officer and President of Berlex Biosciences, a research, development, and manufacturing organization. He founded Burrill & Craves, a merchant bank focused on biotechnology and emerging pharmaceutical companies. He was also the founding Chairman of the Board and Chief Executive Officer of Codon, and co-founder of Creative Biomolecules. Dr. Craves is a member of the boards of directors of Poniard Pharmaceuticals, ProGenTech and VIA Pharmaceuticals. He also serves as a member of The J. David Gladstone Institutes' Advisory Council and is a member of the Board of Trustees of Loyola Marymount University in Los Angeles. Dr. Craves earned a BS in Biology from Georgetown University and a PhD in Pharmacology and Toxicology from the University of California, San Francisco.

Dr. Cronin is currently responsible for leading Genomic Health’s technology and translational research efforts. This includes exploring feasibility in new disease areas and designing analytical processes for high throughput gene expression profiling in specific disease applications. Her team’s efforts include investigating alternative technology platforms, biochemistries and automation solutions for molecular pathology as well as genomic biomarker research and feasibility work in new disease areas. In addition, Dr. Cronin supports the translation of newly adopted technologies into fully integrated work flows in clinical study development programs and carries out the early phase feasibility and exploratory studies for new clinical product concepts.

Prior to joining Genomic Health, Dr. Cronin held several senior R&D positions in biotechnology tool companies including ACLARA BioSciences, Inc. where she was responsible for developing genomic applications for ACLARA’s microfluidic LabCard? (lab-on-a-chip) technologies; Protogene Laboratories where she directed genomics applications for Protogene’s inkjet synthesized, surface tension microarray technology; and, Affymetrix where she played a key role in developing DNA microarray (GeneChip?) technology and several of the array applications.

Dr. Cronin obtained her PhD in Molecular Pharmacology from the University of California, San Diego at the UCSD Cancer Center and earned her undergraduate and MS degrees in physiology at the University of California, Davis. Dr. Cronin’s postdoctoral training was at the San Diego Veteran’s Administration Hospital where she investigated human transcriptional regulation as a host response to HIV and HTLV retroviral infection.

A twenty-year veteran of the medical and life sciences industry, Casper de Clercq observes that innovation in the biotech sector runs in cycles. In the past five years, for instance, there has been extensive adoption of high throughput cell screening assays in the industry. "Over the next five to ten years we will see an emphasis on the integration of those tools and significant acceleration of lead compounds arising out of their application," he says. Because FDA approval and public financing exert a defining influence on the biotech sector, Casper notes, medical device companies have recently been favored while biotech remains a longer term game. USVP has a long track record in biotechnology — founding partner Bill Bowes founded Amgen in the late 1970s — which attracted Casper to the firm. "USVP takes the long term approach. They really stick with companies, using seasoned judgment with regard to risk while supporting the management team in building long term value." Another strength of USVP is the operating experience of its team, Casper notes. "The emphasis here is on deep management experience. We don't get in the way of our companies, but we do get involved with respect to clinical, regulatory and commercialization strategy."

Having joined USVP in 2004, Casper has extensive experience with device innovations in the cardiovascular arena, drug delivery and diagnostics. Given changing conditions in the drug development area, oncology and other therapeutics with an abbreviated regulatory path are of particular interest to Casper. Prior to 2004, Casper was heavily involved in several rounds of financing and the IPO process at Aerogen (AEGN), a specialty pharmaceutical company, where he served as Vice President of Business Development, Sales and Marketing. In 1999 he co-founded Epicor, which was acquired in 2004 by St. Jude Medical at a valuation of more than $200 million. Casper also held senior sales and marketing positions with Heartport (minimally invasive heart surgery) and Diagnostic Products Corporation (immunodiagnostics). At these companies, Casper worked closely with the scientific and engineering teams to define customer requirements and lead product commercialization.

Casper has been through venture financing from the company side many times, and advises: "It's important to get substantial investors early in the process. Yes, you want strategic guidance and good counsel, but it's also important to find VCs that have the financial resources to support several rounds. The commitment to long-term funding can be more important than initial financing terms. Medical investing is an endurance sport." Early in his career Casper worked as a strategy consultant for Bain & Company, working in Boston, Johannesburg and London. Casper holds a B.A. in Biochemistry from Dartmouth and an M.B.A. and M.A. in Biology/Immunology from Stanford University. A fan of aquatic sports, Casper has sailed competitively on the San Francisco Bay and in Europe and windsurfs when the wind gets above 20 knots. He rowed competitively at Dartmouth for four years. He is active with environmental organizations, especially around issues concerned with health and human impact. "The advances in health care have allowed us to live longer—the other half of the equation is how we can minimize human impact on the ecosystems that sustain us."

Keith has over 30 years serving the Life Sciences and Health Care industry in a variety of capacities. He leads the industry practice for Deloitte on the West Coast and serves on the firm's National Life Sciences Management committee. In his capacity he overseas the Deloitte services provided to virtually all of its West Coast biotech and pharmaceutical clients, regardless of the nature of those services. In addition, to his leadership role he also serves as the lead partner serving some of the firm's largest clients in the biotech industry. As a senior partner for Deloitte, Keith has assisted many public companies, international clients and early-stage companies with mergers & acquisitions, IPO services, regulatory matters, capital financing and strategic and operational matters. He has also assisted numerous companies with Sarbanes-Oxley Section 404 readiness and attestation engagements.

He is an active member of a variety of industry associations including BIO, BayBio, Biocom and CHI. Keith is also a member of the Board of Directors for BayBio. He participated in the 2005 UC Berkeley BioExec Institute. He is a frequent speaker and presenter for industry matters at Deloitte presented programs. He is a CPA and a 1975 graduate of the University of Wisconsin - Eau Claire.

Nathalie Dubois-Stringfellow, Ph.D, is currently Senior Director Portfolio Management at XOMA. XOMA focuses primarily on the development of antibody therapeutics for oncology and inflammatory diseases, through phage display selection and engineering.

Nathalie Dubois-Stringfellow obtained her PhD in Human Genetics at the “Université Pierre et Marie Curie” in Paris, France, followed by a postdoctoral fellowship at UNC Chapel Hill, NC, where she studied angiogenesis and tumorigenesis in transgenic mice and cell cultures systems. For 15 years, she has worked at Chiron, Bayer, Signature Biosciences and XOMA implementing and managing preclinical development programs of Biologics in the field of oncology and immune diseases. In the past 5 years, Nathalie Dubois-Stringfellow has been involved in the corporate decision-making process for selecting, optimizing and executing projects within XOMA’s preclinical portfolio.

Ms. Dubrovin is a Senior Global Project Manager at Genentech where currently manages the Lytics franchise projects (Activase®, and Tenecteplase®). Laurie joined Genentech in 2003 and has managed cross-functional early-stage immunology projects and the global Herceptin and Rituxan Immunology programs.

Laurie began her project management career by managing the integration of multiple biological science experiments into a cohesive program for the Space Life Science program at NASA Ames Research Center in California. This experience in international bioscience collaboration management led to a position managing international academic collaborations and early-stage projects for Megabios. Experience managing later stage projects at ALZA Corporation also brought insight into steering teams through significant organizational changes. She has led tripartite global collaboration teams through product development planning, life cycle planning and regulatory filings.

Laurie’s has a Bachelor of Science degree from Colorado State University, a Master of Science degree from University of Nebraska-Lincoln and a Master of Science in Biochemistry from Emory University.

Melanie Ebjojo, M.B.A., PMP, is a senior manager in the product portfolio management group at Genentech. She began her project management career in 1999 at Bayer’s biotechnology division in Berkeley. In 2004, Ebojo joined Genentech, where she manages projects and business improvement initiatives. She is a faculty member for the Pharmaceutical Education & Research Institute.

Mark G. Edwards is the Managing Director of Recombinant Capital, Inc. (Recap), a consulting firm based in Walnut Creek, California. More than 500 biotechnology, pharmaceutical, and service companies subscribe to Recap?s databases (Recap.com & rDNA.com) or retain Recap to advise them on biotech alliances and valuations.

Mr. Edwards has been invited to speak to many trade and industry groups about structuring alliances and other business relationships that are related to the development and commercialization of new technologies, compounds, or products. These groups include the Institute of Medicine, the Licensing Executives Society, the Association of University Technology Managers, Sigma Xi (the Scientific Research Society of the National Academy of Sciences), and the Biotechnology Industry Organization. He has also provided expert testimony at deposition or trial in lawsuits dealing with either reasonable royalties or normal custom and practice in the biotechnology and pharmaceutical industries.

Mr. Edwards is on the Board of Directors of Allos Therapeutics, Inc. Prior to founding Recap in 1988, Mr. Edwards was Manager of Business Development at Chiron Corporation. He received his B.A. and M.B.A. degrees from Stanford University.

Stacy Feld joined Physic Ventures as a Director in January 2009. At Physic, Stacy focuses on personalized health solutions to improve and transform care for the health consumer. Specifically, Stacy is interested in life science opportunities offering more precise prevention, diagnosis, and treatment of chronic disease.

Stacy brings to Physic over ten years of transactional experience in the life science and healthcare industries. Prior to joining Physic, Stacy was Associate Director of Business Development at Genentech, Inc., where she focused on sourcing and accessing novel therapies and predictive diagnostics in the areas of Oncology, Immunology, Ophthalmology, Vascular Biology and Metabolic Diseases. While at Genentech, she worked to establish multiple disease area strategies for the company and led collaboration teams for the evaluation and execution of strategic partnerships and licensing arrangements.

Formerly, Stacy was Director of Licensing and Corporate Development at Third Wave Technologies, Inc., a molecular diagnostics company (since acquired by Hologic, Inc. in 2008), where she was responsible for in-licensing intellectual property to support product development and building strategic relationships with customers, collaborators and suppliers.

Stacy began her career in life sciences as an Associate at Wilson Sonsini Goodrich and Rosati in Palo Alto, CA. As an attorney in the firm's Technology Transactions practice, she advised start-ups and mature companies in the biopharmaceutical and medical device sectors on intellectual property matters and strategic business transactions.

Stacy received a B.A. in Sociology, graduating magna cum laude from the University of Pennsylvania and earned her J.D. from Vanderbilt Law School.

Bio coming shortly.

Geoffrey M. Glass is the Senior Vice President of Strategy, Corporate Development and Integration at Patheon. Mr. Glass is a member of the Executive Management team and leads the company’s global Strategy, Partnership and Acquisition programs, and Marketing functions on a world-wide basis. Immediately prior to Patheon Mr. Glass was the President and founder of a successful consulting business, ClearSciences LLC. Previously, he spent almost five years on the Executive Team at Valeant Pharmaceuticals. Mr. Glass was the Senior Vice President of Asian Operations at Valeant Pharmaceuticals where he had responsibilities for all of Valeant's business affairs in the region which included over 250 products in 14 countries. Prior to leading the Asian business for Valeant Geoff was Senior Vice President and Chief Information Officer of Valeant Pharmaceuticals International. In this role, Mr. Glass was responsible for all information technology-related matters for the company. Prior to joining Valeant, Mr. Glass was the Global Leader of Life Sciences Operations Excellence Practice for Cap Gemini (formerly Ernst & Young LLP Consulting). During his tenure at Cap Gemini, Mr. Glass led global teams through the successful implementation of business and IT transformations at a number of leading life sciences organizations. Mr. Glass earned his bachelor of arts in Economics and Political Science at the University of Arizona.

Since May 2008, Dr. Goure has been President and CEO for Acumen Pharmaceuticals. Dr. Goure has over 20 years of domestic and international experience in the discovery, development, registration, commercial development, and commercialization of chemical and biotechnology products.

Prior to joining Acumen, Dr. Goure was Vice-President for Commercial Development for Mendel Biotechnology, a bay area company dedicated to creating value through the discovery, development and commercialization of knowledge about plant gene expression. At Mendel, Dr. Goure negotiated numerous technology collaboration and partnership agreements that generated over $29 million dollars of near term revenues.

Prior to joining Mendel, Dr. Goure worked for Monsanto Company for 17 years where he developed and commercialized Roundup Ready® soybeans, canola, and cotton. Dr. Goure was a member of the team that established Monsanto’s quality traits program that led to the Renessen joint (partnership) with Cargill, and was responsible for establishing commercial launch teams in Eastern Europe, South Africa, and Southern Latin America.

Dr. Goure has a B.S. degree in Chemistry from Fort Lewis College, Durango Colorado, and a Ph.D. degree in organic chemistry from Iowa State University. Prior to joining Monsanto, Dr. Goure was a Post-Doctoral Fellow at Colorado State University.

Anton Gueth has over 20 years experience in the healthcare industry. Prior to joining Burrill & Company, Mr. Gueth was President of Gueth Consulting, a firm specializing in business development and alliance management in the life sciences industry. A recognized expert in alliance management, he collaborates with Vantage Partners to provide clients access to world class expertise in orchestrating strategic alliances for pharmaceutical and biotech companies. As a business development consultant he supported early stage companies with an outsourced business development model and also held the position of Chief Operating Officer for a start-up software company, Collaborative Drug Discovery (CDD).

Prior to establishing his own consulting firm in 2003, Mr. Gueth worked with Eli Lilly and Company for 20 years holding a number of operational positions in corporate and business development, general and financial management, sales and marketing. Most notably, as Director of Alliance Management, he led Eli Lilly's efforts to become the "pharmaceutical partner of choice."

Mr. Gueth is a member of the Board of Directors of Antares Pharma, a specialty pharmaceutical company with an emphasis on delivery technology, and a member of the Board of Directors of the American Liver Foundation, California Chapter.

Ashraf Hanna, 38, will join Genentech in a newly created position as vice president, Alliance Management and Portfolio Planning, reporting to Susan Desmond-Hellmann, M.D., M.P.H., president, Product Development. Working with Business Development, the Project Portfolio Management Group, and Research and Development, Hanna will be responsible for establishing, implementing and evaluating alliance management strategy and process.

Prior to joining Genentech, Hanna was vice president at Tanox, with responsibilities for strategic planning and business development. Prior to that, Hanna worked for McKinsey and Company and was a medical resident at Metrowest Medical Center.

Hanna holds a Bachelor of Arts degree in Physics from the University of Chicago, a doctorate in Physics from Harvard University and a medical degree from the University of Massachusetts Medical School.

Dr. Laurel Hacche is a Director of Worldwide Quality Assurance for Allergan, Inc. She currently has QA oversight for the corporate audit program, annual product reviews, government agency communication records, third party manufacturers, the global stability program, complaint management, and R&D technology transfer. In addition to the above activities, she serves as the lead corporate QA liaison for FDA and alternate regulatory agencies. Dr. Hacche has been with Allergan, Inc. for 18 years. Prior to Allergan, Inc., she served as a Postdoctoral Researcher in the Dept. of Biological Chemistry at the California College of Medicine at U.C. Irvine. She has held an Associate Faculty position at the Math, Science, and Engineering Department at Saddleback College and served as an Assistant Professor at the Joint Science Department for The Claremont Colleges. Dr. Hacche holds a Ph.D. in Physical Polymer Chemistry from U.C. Irvine and an A.B. in Chemistry from Occidental College.

Judith A. Hasko is a partner in the Silicon Valley office of Latham & Watkins. Ms. Hasko is a member of the Technology Transactions and the Health Care and Life Sciences practice groups. She also currently serves as a member of the firm's Global Recruiting Committee.

Ms. Hasko's practice focuses on representing biotechnology, pharmaceutical, medical device and other companies and investors in a wide range of technology-based commercial transactions. She works with both private and public companies in domestic and international transactions, counseling such companies with respect to corporate partnering, joint venture, asset purchase, spin-out, licensing, distribution, manufacturing, co-development, profit-sharing and co-promotion matters. She also advises investors with respect to licensing and intellectual property matters arising in private and public offerings by life sciences companies.

Ms. Hasko's representative transactions include advising Corgentech in its co-development, co-promotion and profit-sharing agreement with Bristol-Myers relating to a phase 3 clinical stage product, potentially worth more than $550 million; representing Tularik in its collaborations and licenses with companies such as Eli Lilly & Co, Japan Tobacco and Amgen; advising Nektar Therapeutics in its largest and most comprehensive deal to date -- an agreement with Bayer HealthCare to develop and commercialize NKTR-061, an inhaled amikacin for the treatment of pneumonias, which may yield up to $175 million in payments to Nektar; and working with clients such as Abgenix and Gilead in various strategic licensing and IP matters, including collaborations with domestic and international pharmaceutical companies. She joins Latham & Watkins from the Palo Alto office of Cooley Godward LLP, where she was a partner in the firm's life sciences practice since 2001.

Ms. Hasko received her J.D. degree cum laude in 1994 from the University of Wisconsin Law.

Ms. Heller is Executive Vice President of Business Development at Exelixis and has more than 15 years of legal and business development experience in the pharmaceutical and biotech industries. Prior to joining Exelixis, Ms Heller was Head of Strategic Alliances at Novartis Pharmaceuticals where she was responsible for transactions with partners in the pharmaceutical and biotech industry as well as academic institutions worldwide. Prior to joining Novartis, Ms. Heller was Vice President, Corporate Development and Legal Affairs at Signature BioScience, Inc. a drug discovery company focused in oncology. Previously, she was Corporate and Intellectual Property Counsel for Celera Genomics, where she was the head of the legal department and responsible for negotiating corporate and business transactions and collaborations. She has also held several positions of increasing responsibility in the areas of business development, licensing, and sales & marketing.

Ms. Heller is a member of the California State Bar, is licensed by the US Patent and Trademark Office and has a B.S. in biology from Tulane University an M.A. in biology from American University and J.D. from Golden Gate University School of Law.

Terry Hisey serves the Life Sciences industry in bringing Tax, Audit, Consulting, and Financial Advisory Services to assist clients in achieving sustainable competitive advantage through strategic change. The Life Science activities span the entire value chain including Drug Discovery & Development, Commercial Operations, Production & Distribution, and Regulatory Compliance. In addition to Life Sciences, his responsibilities also include linking the Life Science effort with those in Health Providers, Health Plans, and Government to identify and capitalize on the unique capabilities that Deloitte could offer based on our depth in all aspects of the value chain. Terry is Chairman of the Life Sciences Advisory Board for Deloitte Research and is a Steering Committee member for the Deloitte Center for Health Solutions in Washington, DC working with The Honorable Tommy Thompson, Former U.S. Secretary of Health and Human Services.

Terry was previously the Vice President and National Leader of the Life Science Practice of a major global consulting & integration firm and was a global leader in their efforts regarding Life Science thought leadership in strategy, transformation, and operations. He has personal client service experience with a number of Pharmaceutical and Biotechnology firms that includes Amgen, Merck, Abbott, Genentech, Pfizer, GlaxoSmithKline, Wyeth Biopharmaceuticals as well as other major and mid-size Life Science companies.

In addition to his client work, Terry is a noted industry authority, a frequent speaker, the Strategy Advisor to Pharmaceutical Executive Magazine and a guest lecturer at several schools including the University of Pennsylvania and Drexel University. In addition, Terry is a member of several industry associations and advisory boards and he is the Deloitte sponsor for the William and Phyllis Mack Center for Innovation at the Wharton School of the University of Pennsylvania. Terry has a BS in Engineering from Penn State and a MS in Business & Organizational Management from the University of Pennsylvania.

P.J. Honerkamp is Deputy General Counsel for Jazz Pharmaceuticals, Inc. Mr. Honerkamp joined Jazz Pharmaceuticals in 2004 and is responsible for corporate legal matters including licensing and acquisitions, clinical trials, commercial contracts and debt and equity offerings. Prior to joining Jazz Pharmaceuticals, P.J. was an attorney at the law firm of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP where he focused on corporate and securities law; private, public and commercial financings; mergers and acquisitions; licensing and strategic transactions; and venture fund formations. He received his J.D., cum laude, from Harvard Law School and his bachelor's degree, magna cum laude, from Davidson College.

Chris Horan is currently vice president, Planning, Distribution and Logistics at Genentech. In this role, Chris is responsible for product and materials planning for Genentech's entire supply chain. Chris joined Genentech in 2004 and was charged with creating and building operational excellence capabilities for Product Operations. Prior to Genentech, Chris was with Merck & Company, Inc. for 16 years. During his tenure with Merck, Chris was responsible for leading international manufacturing projects in 9 countries, including ex-pat assignments in Australia, China, and Korea. Chris played a key role in shaping Merck's Global Operational Excellence organization by providing OE leadership to its marketing and sales division, focusing on the Japan market. Chris graduated from the Stevens Institute of Technology in Hoboken, New Jersey with a Bachelor of Engineering degree.

As national managing partner, biotechnology, for Deloitte & Touche USA LLP's Life Sciences & Health Care practice, Matthew Hudes is a seasoned professional with more than 17 years of experience in a broad array of biotechnology arenas. As practice leader in this dynamic sector, Matthew directs strategic professional services for leading biotechnology and pharmaceutical companies.

Before joining the Life Sciences & Health Care practice, Matthew worked extensively within the biotechnology arena, including being chief executive officer of a software company that developed a system to find patients (and investigators) for clinical trials to improve researchers' access to information typically "trapped" in laboratory and medical systems. He has directed the management teams of three successfully acquired biotech start-ups and has worked with many leading-edge companies in life sciences and high technology.

He speaks frequently about the use of technology for innovating clinical research, manufacturing and quality, regulatory compliance, supply chain and other topics. He also has written extensively about the business of biotechnology.

Mohan brings a broad life sciences background in a range of functions including business development, strategic planning, marketing, product development, engineering and manufacturing. Prior to joining Burrill & Company, he was Executive VP of Corporate Development at diaDexus, Inc. where he was responsible for sourcing and executing various types of transactions during a seven year period, including in-licensing, out-licensing, and a successfully executed spin-out of the therapeutics division. While at diaDexus, he played a key role in two major private financings, managed R&D operations for a transition year, and headed the marketing launch of a novel cardiovascular diagnostic product. Prior to diaDexus, Mohan was a healthcare consultant at The Wilkerson Group where he managed several strategic engagements across the pharmaceutical, biotech, diagnostics and medical device industries. Mohan began his biotech career as a biochemical process engineer at Genentech, where he spent 7 years in positions ranging from biopharmaceutical manufacturing to capital projects management. He holds a BS in Chemical Engineering (Tennessee), an MS in Biomedical Engineering (Duke), and an MBA (Yale).

Rob Jacoby is a Senior Manager in Deloitte's Strategy and Operations practice focused on commercial operations in the life sciences industry. Rob’s engagements with Deloitte have spanned commercial and operational strategy at major biotechnology and pharmaceutical manufacturers. Rob has spoken to regional and national audiences on market entry strategy and the emerging landscape for biopharmaceutical distribution, and has published numerous articles and whitepapers on commercial strategy in life sciences, including Avoiding No Man’s Land: Potential Consequences of Follow-On Biologics. In ten years of professional experience prior to joining Deloitte, Rob served on the management teams of several entrepreneurial organizations in healthcare, technology, business services, social services, and the performing arts. Rob received an AB from Harvard College and an MBA from the Haas School of Business at UC Berkeley.

Jennifer Jarrett is a Director in the Health Care Group within the Credit Suisse Investment Banking Department, based in San Francisco. She has more than ten years of investment banking at Credit Suisse focused on biotechnology, with three years of investment banking at Merrill Lynch and Kidder Peabody. Ms. Jarrett received her MBA from Stanford University and her bachelor's from Dartmouth College.

Suzy Jones is Senior Director of Business Development at Genentech, Inc. As a member of the Business Development team, Suzy heads-up a group of licensing professionals responsible for building out Genentech's pipleline outside of the area of Oncology. Her group is responsible for identifying new opportunities that will support the company's short- and long-term strategic objectives and negotiating and structuring collaboration agreements to support the newly formed strategic alliances. Suzy's career includes 18 years of biotech experience. She spent 7 years conducting basic Immunology Research evaluating the role of adhesion molecules in inflammation, 4 years in Product Development where she managed several pipeline products at various stages of their lifecycles, including Rituxan, Avastin, and Raptiva, and 7 years in business development overseeing Genentech's licensing efforts in Immunology, Tissue Growth and Repair, New Therapeutic Areas and Technology Licensing.

Dr. Abhay Joshi is the President, CEO and Director of Alvine Pharmaceuticals, Inc. He has over eighteen years of global operations and research and development experience in biologic, pharmaceutical and medical device industries in the United States, Europe, Latin America and Asia Pacific. Prior to Alvine, Dr. Joshi served as an Executive Vice President, Chief Technical Officer and member of Executive Committee at CoTherix, Inc., now Actelion Ltd. Dr Joshi held various senior management positions at Allergan. He was the Vice President of Global Technical Operations, Specialty Pharmaceuticals at Allergan where he was responsible for the company's global biologics manufacturing operations for BOTOX® and its Latin America and Asia Pacific pharmaceutical operations. Dr. Joshi received his BTech in Chemical Engineering from the Indian Institute of Technology, New Delhi, an MSE and a Ph.D. in Chemical Engineering from the University of Michigan, Ann Arbor, and an MBA from the University of California, Irvine. Dr. Joshi holds an adjunct faculty appointment at the University of Southern California School of Pharmaceutical Sciences.

Harris Kaplan is currently President and Chief Executive Officer of Healogix, a consultancy that advises companies on how to create and maximize the value of new products in development.

Harris has extensive experience in the pharmaceutical industry both on the client and consulting side of the business. Harris co-founded Migliara-Kaplan Associates which became the world?s largest custom marketing research company serving 19 of the top 20 pharmaceutical companies. Migliara-Kaplan Associates specialized in helping companies identify new product opportunities and then maximizing the commercial potential of new products in development. Migliara-Kaplan was acquired by NFO in 1996 and is now part of TNS Healthcare.

Harris was also cofounder of Cozint Interactive which was acquired by GFK, the German based research company. Harris serves as an advisor to several venture capital funds and is on the Board of Directors of Informed Medical Communications, Informedix, and the Kernan Orthopedic Hospital.

Ann Lee-Karlon currently serves as a Senior Director of Product Portfolio Management at Genentech. She leads a cross-functional project team that is responsible for the life cycle strategy and development of anti-CD20 therapies (Rituxan and second generation anti-CD20) for autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. She also serves as therapeutic head of the Project Team Leaders group in Immunology and Tissue Growth/Repair, which leads project teams in early development through launch and on the market.

Prior to Genentech, Ann worked in venture development at Eli Lilly. She has worked previously at a biotech in La Jolla (ATS) and interned at Pfizer in New York and at UBS investment bank in London. Ann holds an MBA from Stanford University, a BS in Bioengineering from UC Berkeley, and a PhD in Bioengineering from the UC San Diego, where she was a National Science Foundation Fellow. She completed a postdoctoral fellowship at the University College London as an NSF International Research Fellow.

Dr. Keckley, is Executive Director for the Deloitte Center for Health Solutions ("the Center"), a part of Deloitte & Touche USA LLP. In this role, Dr. Keckley provides strategic guidance on the development of Center research and thought leadership. Dr. Keckley brings to Deloitte 30 years of experience in academic medicine and the private sector. He is regarded as a primary expert in health care economics, health policy and trend analysis.

Prior to joining Deloitte, Dr. Keckley served in several key roles at Vanderbilt University. He was the Executive Director of the Vanderbilt Center for Evidence-based Medicine (VCEBM), Associate Professor at Vanderbilt University School of Medicine, and an Associate Professor of Health Management at the Owen Graduate School of Business. He continues to teach in the Schools of Medicine and Business on an adjunct basis.

In the Center for Evidence-based Medicine, he conducted research evaluating how consumer adherence to evidence-based treatment directives might be achieved, how health insurers incorporate evidence in their coverage and pay for performance programs, and methods for integrating evidence-based practices in provider organizations.

Dr. Keckley led efforts by the Vanderbilt Medical Group to develop, integrate and measure adherence to evidence-based pathways and order sets. He led Vanderbilt joint ventures involving clinical outsourcing in domestic and international settings and spearheaded Vanderbilt's entry into integrative health, with the anticipated opening of the Vanderbilt Center for Integrative Health scheduled for November 2006.

Before joining Vanderbilt, Dr. Keckley served as Chairman of the Board of Interdent, a California dental practice management company; Chief Executive Officer of EBM Solutions, a developer of evidence-based guideline software; Chief Executive Officer of Aveta (formerly the IPA Management subsidiary of PhyCor Inc.), and Principal of The Keckley Group, a strategic planning consulting practice that served 1,200 U.S. provider organizations and health plans.

Dr. Keckley is an active member of several societies and editorial boards, and has authored numerous articles and three books. He has been profiled by ABC's 20/20, CBS's 60 Minutes, Fox News, CNN, The Wall Street Journal, and has been featured as a keynote speaker at several national industry meetings. Dr. Keckley has also testified for state Medicaid Review Committees in Utah and Tennessee about the potential impact of evidence-based standards on benefits for enrollees.

Dr. Keckley received a B.A. from Lipscomb University, his MA/PhD from Ohio State University, and completed a fellowship in economic policy at Oxford University.

David A. Kessler, MD, was until recently the dean and vice chancellor for medical affairs at UCSF School of Medicine. Before joining UCSF in the fall of 2003, Dr. Kessler had been Dean of the Yale University School of Medicine since July 1997. Dr. Kessler, who served as Commissioner of the United States Food and Drug Administration from November 1990 until March 1997, was appointed by President Bush and reappointed by President Clinton.

As commissioner of the FDA, he acted to speed approval of new drugs and placed high priority on getting promising therapies for serious and life-threatening diseases to patients as quickly as possible. He introduced changes in the device approval process to make it more efficient and ensure that it meets high standards. Under his direction, the FDA announced a number of new programs, including: the regulation of the marketing and sale of tobacco products to children; nutrition labeling for food; user fees for drugs and biologics; preventive controls to improve food safety; measures to strengthen the nation's blood supply; and the MEDWatch program for reporting adverse events and product problems. He emphasized strong law enforcement and created an Office of Criminal Investigation within the agency. According to The New York Times (11/27/96), David Kessler " revitalized a beleaguered agency that had become mired in bureaucratic disarray." The Los Angeles Times (11/27/96) praised him for " restor[ing] the Food and Drug Administration to what it was meant to be - an aggressive advocate for the public's health." With his departure, "[t]he American people lost one of their most effective champions" (New York Daily News, 11/28/96).

Dr. Kessler has a wide range of experience in research, clinical medicine, education, administration, and the law. He is a 1973 magna cum laude, Phi Beta Kappa graduate of Amherst College. He received his J.D. degree from The University of Chicago Law School, where he was a member of the Law Review, in 1978, and his M.D. degree from Harvard Medical School in 1979. He did his internship and residency in pediatrics at the Johns Hopkins Hospital. In 1986, he earned an Advanced Professional Certificate from the New York University Graduate School of Business Administration.

Dr. Henk Kocken joined Alvine Pharmaceuticals as Vice President of Quality and Regulatory Affairs in June of 2007. Dr. Kocken has held various academic and industry positions for over twenty years with increasing responsibility in quality management and compliance, and specializes in building company-wide quality systems compliant with cGMP, FDA and worldwide regulations and ISO-9000. Prior to joining Alvine Pharmaceuticals, Dr. Kocken served as Head of Quality at KaloBios, Inc. and Vice President, Quality Systems at VaxGen, Inc. In addition, he has held leadership positions at CoTherix, InterMune, FibroGen, BioRad and Clontech. Before relocating to the United States, Dr. Kocken was Assistant Professor Molecular Biology at Eindhoven University of Technology in The Netherlands. Dr. Kocken holds a Bachelors degree in Biochemistry and a Masters degree in Molecular Biology, both from Nijmegen University, The Netherlands and received his Ph.D. in Chemical Technology from Eindhoven University of Technology, The Netherlands.

Bio coming shortly.

Mr. Maher joined BioMarin as vice president, program management in August 2003, bringing with him over 20 years of biotechnology industry experience. He is currently responsible for program management and research. From 1998 to 2003, Mr. Maher worked at Aradigm Corporation serving as vice president, program management. Prior to Aradigm, he served as director of clinical operations at Covance, Inc., and as vice president of operations at Spectra BioMedical, Inc. Prior to Spectra, Mr. Maher acted as director, therapeutics project management, at Chiron Corporation. Mr. Maher started his career at Genentech, Inc. in 1981, serving in several capacities in operations, and as Manager of Product Development. Mr. Maher received an M.B.A. in health services management from Golden Gate University and a B.A. in biology from San Francisco State University.

Peter McWilliams is a Principal with Sanderling Ventures and has more than 15 years experience in biomedical research and management. He works with several Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team. Portfolio companies include Trinity Biosystems, Artielle Immunotherapeutics, Actimis Pharmaceuticals, Harkness Pharmaceuticals, Cylene Pharmaceuticals and others.

Prior to joining Sanderling, Dr. McWilliams worked at Genentech (NYSE: DNA) where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin®. Prior to that he was an Associate with Booz.Allen & Hamilton in San Francisco where he focused on projects for major US and International life science companies. From 1991 to 1994 he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics where, as a Product Manager and Applications Specialist, he helped to set up and establish their US operations prior to their successful IPO on the London Stock Exchange in 1994.

Dr. McWilliams received an M.B.A. from Columbia Business School in 1996, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. in 1991 and an M.A. in 1990 in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University in 1987.

Catherine Mesner is a Sr. Manager in Deloitte & Touche’s Life Sciences Regulatory and Compliance practice. She has 24 years of experience at various pharmaceutical companies, including over a decade at Eli Lilly. After which she joined a global Contract Research Organization (CRO) leading a regional Clinical Operations department before taking her experience to help build foundations at within emerging pharma companies. Her area of expertise is Clinical Development and Operations Regulatory Affairs, and Healthcare Compliance.

She is a cross-trained professional with direct operational experience in clinical development/operations and regulatory affairs from IND-enabling processes through commercialization phase. The portfolio of product approvals Catherine has managed in her career speaks to the integrity of the product development processes she has implemented. Development of standard policy and procedures aligned with applicable regulations and GxP coupled with robust training result in quality submissions. Early adoption of standard processes can eliminate redundancy, reduce costs, expedite timelines. The depth of her experience and breathe of knowledge balances the quality and regulatory expectations within pharmaceutical development to decrease variability and risk.

Dr. Molineaux co-founded Proteolix in December 2003 and served as the Company’s Chief Scientific Officer. From January 2006 until February 2009, she served as the Company’s Chief Executive Officer, at which time she transitioned back to the role of CSO with responsibility for all research, development and clinical affairs activities. Prior to joining Proteolix, Dr. Molineaux was Vice President, Biology at Rigel Pharmaceuticals from 2000 to 2003. Before that, she was Vice President, Biology at Praelux, and from 1994 through 1999, Dr. Molineaux served as Vice President of Drug Development at Praecis Pharmaceuticals. From 1989 until 1994 she was a scientist in the Immunology group at Merck, in Rahway, NJ. Dr. Molineaux received a B.S. in Biology from Smith College, a Ph.D. in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.

Effective December 15, 2006, Thomas Moore was named our Chairman and Chief Executive Officer. He is currently also Director at Alteon, Inc., a publicly traded developer of pharmaceuticals for the treatment of diabetes and age-related diseases, El Dorado Inc., a targeted marketer to unassimilated Hispanics, Medmeme, which measures medical education effectiveness, MD Offices, an electronic medical records provider, and Opt-e-scrip, Inc., which markets a clinical system to compare multiple drugs in the same patient. He also serves as Chairman of the Board of Directors of Mayan Pigments, Inc., which has developed and patented Mayan pigment technology. Previously, from June 2002 to June 2004 Mr. Moore was President and Chief Executive Officer of Biopure Corporation, a developer of oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. From 1996 to November 2000 he was President and Chief Executive Officer of Nelson Communications. Previously, Mr. Moore had a 23-year career with the Procter & Gamble Company in multiple managerial positions, including President of Health Care Products where he was responsible for prescription and over-the-counter medications worldwide, and group vice president of the Procter & Gamble Company.

Gareth Morgan is Head of Central Clinical Operations at Bristol-Myers Squib. He leads a department responsible for operational implementation of BMS clinical development programs executed globally. Gareth started his pharmaceutical career with Hoechst-Roussel Pharmaceuticals Inc. (now Sanofi-Aventis) in Clinical Operations and Project Management. As a Project Manager he successfully led research and development teams, including submission and approval of an NDA and several s-NDAs. In the mid-90s he joined Genentech Inc. where he was responsible for Portfolio Planning and Analysis, providing senior management with guidance regarding development cost and risk. In 1998 he was recruited by Bayer Pharmaceuticals where he was appointed Director of US Project Management and later Vice President of Global Clinical Project Management. In both roles he operated across all therapeutic areas, providing management and leadership for team leaders responsible for multiple regulatory submissions and product approvals

The BMS Central Clinical Operations department consists of Operations Leads, Protocol Managers, and Clinical Trial Associates and totals more than 200 personnel. Operations Leads are each responsible for running one global clinical program from an operational perspective. Protocol Managers lead the planning and execution of specific clinical studies. Clinical Trial Associates support the Operations Leads and Protocol Managers as needed. In a recent KMR benchmarking analysis of thirteen major pharmaceutical companies, BMS received the highest composite score for development performance, driven by excellence in operational cycle time and cost.

Gareth holds an MS in Biological Science and an MBA. Gareth and his family reside in Princeton, NJ. He splits his time between BMS facilities in Lawrenceville, NJ, Wallingford, CT, and Brussels, Belgium.

Mr. Robert Murphy has more than 35 years of experience in biological, device, pharmaceutical and health care products manufacturing, quality assurance, and research and development. Mr. Murphy, Vice President, Worldwide Quality Assurance is responsible for Allergan’s worldwide Quality operations and third party suppliers. His expertise is in leading sterile manufacturing, Quality Assurance & Control and Regulatory compliance operations for global OTC, Rx and controlled substance, Biological, Drug and Device products. He has led Corporate Global Quality and Compliance and plant operations for several multinational companies, ensuring compliance with quality standards, policies and all legal and regulatory requirements and timely support of global business goals. Achieved numerous first time PAI recommendations from US and foreign inspectorates and achieved key product global launch supply goals for block buster drugs. During his career he has held key operational and quality leadership positions at Allergan Inc, Pharmacia, Searle a Monsanto Co, Altana Inc., Revlon Health Care Inc. and, Warner Lambert. He holds a Bachelor of Science degree from The City College of New York and an M.B.A. from Saint John’s University.

Theresa Kane Musser is Executive Director of Development Operations at Rigel Pharmaceuticals in South San Francisco, CA. She is responsible for the project management, clinical operations and regulatory submission departments for the company. Prior to her current position, Theresa worked at Genentech, Inc. for 11 years where she held a variety of positions including heading the departments Project Management, Clinical Operations for the Pulmonary Therapeutic Unit and Business Operations (for the Clinical Department). She worked at SmithKline for 8 years where she did international clinical development of cardiovascular drugs and project management in a variety of therapeutic areas. Theresa started her career in the pharmaceutical industry as a Clinical Research Associate for Ayerst. She received a BA in Biology from UC Santa Cruz. Theresa is an active member of several industry organizations including the Project Management Institute and is Immediate Past President of the Drug Information Association.

Dr. Patzer has 22 years experience in product development beginning his career at Genentech in 1981. Dr. Patzer played a key role in the development of Activase®, Protropin®, Herceptin® and Xolair®. As Vice President, Product Development, Dr. Patzer's responsibilities included analytical development, hybridoma development, preclinical animal testing, QA/QC and project and portfolio management. Dr. Patzer played a key role in developing the product development and management process at Genentech.

In 1996 Dr. Patzer joined Aviron (now MedImmune Vaccines) as Vice President, Development. Under his leadership, the Development organization was expanded to support the development of the intranasal influenza vaccine (FluMist®) through preclinical and clinical development and resulting in U.S. regulatory approval (FDA). The organization consisted of the following departments: analytical development, clinical QC testing, process and formulation development, clinical manufacturing, clinical laboratory testing and project management. Dr. Patzer was the project team leader of the intranasal influenza vaccine, FluMist®, during preclinical and clinical development.

In 2003, Dr. Patzer founded Aridis Pharmaceuticals, LLC to develop convenient and cost effective therapeutics for infectious diseases focused on live attenuated vaccines and antibody therapies that can be delivered in simple oral or pulmonary dosage forms and that can be stored outside the cold chain (i.e., are stable at room temperature and above). Aridis is currently developing two temperature stable oral vaccines against rotavirus gastroenteritis in infants and shigellosis in adults and children and a temperature stable antibody therapeutic against pulmonary infections with Pseudomonas aeruginosa.

Brian Pelkowski has been at Genentech for over six years. He moved into his current role as Associate Director, Project Team Leadership within gRED (Genentech Research and Early Development) in April this year. In this role Brian is responsible for developing and executing life cycle strategis and plans for Phase I and II molecules. Prior to this transition, Brian spent over two years in Marketing as both the Strategy and Physician Promotion Lead for Rituxan for RA. In this role, Brian led the three-year brand planning, launch readiness and competitive response teams. Brian’s other roles at Genentech were in Market Planning where Brian and his group were responsible for assessing the commercial value and recommending the commercial strategy for internal and external oncology development opportunities. Before joining Genentech, Brian spent over five years as a consultant to pharmaceutical and biotechnology companies working on valuations, mergers and asset allocation projects. Brian received an MBA from the Kellogg School of Management

Catherine M. Polizzi is a partner in the Palo Alto office and Co-Chair of the firmwide Intellectual Property group of Morrison & Foerster LLP. Dr. Polizzi focuses her intellectual property practice on patent law and biotechnology.

Dr. Polizzi has a wide range of experience in patent law and technology, working with small, medium and large companies as well as universities. Dr. Polizzi provides patent portfolio strategic counseling and comprehensive portfolio management for emerging as well as mature life science companies. She is involved in all aspects of patent prosecution and procurement. Dr. Polizzi's practice also includes due diligence evaluation and counseling. Dr. Polizzi provides counseling for intellectual property strategy and implications during all stages of product and project development. Her practice also includes patentability, freedom of operation, infringement, and validity evaluations and opinions. Dr. Polizzi has significant experience in technology transactions, as well as patent litigation and interference.

Dr. Polizzi holds a Ph.D. in Molecular Biology and Biochemistry from the University of California, an M.A. in Chemistry from the University of California, and a B.A. with distinction in Chemistry from the University of Mississippi. Dr. Polizzi received a J.D. from Stanford Law School, where she was awarded the Hilmer Oehlmann, Jr. Award for Legal Research and Writing.

Michael was born in Brantford, Ontario, the same town as Wayne Gretzky, but he can't play hockey nearly as well. He holds an undergraduate degree in Philosophy from Harvard College (1990) in Cambridge, MA, where he graduated Magna cum Laude. His thesis on the metaphysics of personal identity has left him absolutely sure he has no idea who he is. During the course of his undergraduate career he was a Detur Prize winner for first-year academic excellence and a John Harvard Scholar for continued academic excellence. He has an MBA (1994) from the Richard Ivey School of Business in London, Ontario, where he was awarded the Nelson M. Davis Memorial Scholarship. He earned his Doctorate in Business Administration from the Harvard Business School (2000) with a dissertation on the sources of corporate value-added in diversified firms. He also earned the Dively Award for research excellence.

At Deloitte Consulting LLP, Michael is the Distinguished Fellow with Deloitte Research. He works with senior executives in the world's leading corporations across a wide range of industries, including telecommunications, media and entertainment, pharmaceuticals, medical devices, energy, and manufacturing. His client work, research, writing, as well as his speaking engagements focus on generating returns — competitive strategy — and reducing risk ? corporate strategy.

Michael's first book, co-authored with Clayton M. Christensen, The Innovator's Solution, was published in 2003, and became a bestseller. The focus of the book was on creating and sustaining successful growth. Michael?s second book, The Strategy Paradox, was published by Doubleday in February 2007. This book is about how to reduce risk without sacrificing returns.

Peter is a principal in our Life Sciences Strategy & Operations Practice with over 15 years of consulting experience. Peter’s R&D experience includes transformational change programs in clinical development, regulatory affairs, and product safety. He has executed projects to increase revenue and decrease cost and cycle time for global pharmaceutical companies, biotechs, CROs and medical device companies. He has experience in startups, business capability redesign, sourcing strategies, financial analysis, performance improvement and business planning.

Prior to joining Deloitte Consulting, Peter was a partner in the global Pharmaceutical and Medical Products practice at Accenture, where he was responsible for leading their Clinical Development Business Process Outsourcing practice for North America.

He holds an MBA in Finance and Policy from the University of Chicago Booth Graduate School of Business and a BS in Mechanical Engineering from the University of Illinois.

Barbara Ryan is a Managing Director at Deutsche Bank Securities Inc., and joined the firm (formerly Alex Brown & Sons), in April 1992 as a senior analyst covering the Large Cap U.S. Pharmaceutical Industry. Barbara has been covering the US Pharma sector for 25 years (since 1982), and while at Alex Brown, also covered the PBM industry, healthcare distributors, as well as the drug wholesalers, and some specialty pharma companies. In 2005, she extended her coverage to include the U.S. drug distributors. Barbara has been recognized by the Wall Street Journal All-Star Analyst survey, and is a four-time member of the Institutional Investor All-America Research Team Prior to joining Deutsche Bank, Barbara was a senior analyst at Prudential Securities, for two years, and began her sell-side career at Bear Stearns, in 1981. Barbara studied at the University of Massachusetts, and majored in Finance. Barbara lives with her husband, Al Filippone, and their two sons in Connecticut, and participates in USTA league tennis competition.

Lucy Rose is uniquely qualified to provide regulatory training and consulting to the pharmaceutical industry and its service support providers, such as public relations firms, advertising agencies and CME providers. Her combination of education and experience, coupled with her extensive experience as a trainer and educator, provides the depth of knowledge and expertise necessary to equip companies to face a promotional environment changing at warp speed.

From 1995-97, Lucy served as the Director of Office of Training and Communications for the Center for Drug Evaluation and Research (CDER) of the Food and Drug Administration. There she designed and implemented programs to improve external communications with consumers, patients, the pharmaceutical industry and health care professionals. Additionally, she designed and implemented programs to improve employee performance, including leadership and management development. Examples of programs introduced during Lucy?s leadership include: design and implementation of CDER's World Wide Web Site, Live Satellite Educational TV programs with the pharmaceutical industry, comprehensive introductory training programs for new reviewers, and design and implementation of CDER's crisis communication program.

Lucy led CDER's Division of Drug Marketing, Advertising and Communications (DDMAC) from 1993 to 1995. In this capacity, she was responsible for the regulatory oversight of all prescription drug advertising and marketing to U.S. health care professionals and consumers. Under Lucy?s leadership, the division intiated a philosophy of transparency and educational outreach, in addition to setting clear review priorities and timeliness goals for industry-requested comments, such as voluntary submissions of launch campaigns. Special challenges encountered during her tenure included the FDA Industry Supported Scientific and Education Guidance and the evolution of Direct-to-Consumer Broadcast advertising, among others.

Prior to joining FDA, Lucy was associated for seven years with Mead Johnson Pharmaceuticals, a division of Bristol-Myers Squibb Pharmaceuticals. She began her career as a sales representative, served as a regional sales trainer, and for four years was the District Sales Manager in Washington, DC. Lucy earned a B.S. degree in biology from Salem College in Winston-Salem, NC and an M.B.A. from Averett College. In addition, Lucy practiced as a board-certified Physician Assistant, having graduated from the Wake Forest School of Medicine.

Lucy has been honored with a number of awards. The FDA twice selected her for their highest leadership accolade, the Award of Merit, for her work at DDMAC and at Office of Training and Communication. In 2004, Phame, an award organiation that evaluates Direct-to-Consumer promotion, elected her to its DTC Hall of Fame for her many years of leadership in the DTC arena. Additionally, Lucy speaks extensively at professional conferences on the regulatory and compliance issues surrounding the promotion of prescription drugs. She is an active member of the Drug Information Association and the Food and Drug Law Institute.

Patrick J. Scannon, M.D., Ph.D. is XOMA's Company Founder, Executive Vice President, Chief Medical Officer and a member of the Board of Directors of XOMA Ltd. Since 1980, Dr. Scannon has directed the Company's product identification, evaluation and clinical testing programs. As Chief Biotechnology Officer, he heads the clinical and preclinical research programs, evaluating several classes of biologic compounds and conducting clinical studies for infectious, oncologic and immunologic indications.

Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and a medical degree from the Medical College of Georgia. He completed his medical internship and residency at the Letterman Army Medical Center in San Francisco. A board-certified internist, Dr. Scannon is also a member of the American College of Physicians. He has served as a Trustee of the University of California Berkeley Foundation and is a member of the University of California Berkeley Chancellor's Community Advisory Board. He has served or is serving on the boards of several companies and institutions, and is currently a member of the DSRC (Defense Sciences Research Council), an advisory board for DARPA (Defense Advanced Research Projects Agency) and also a member of the Department of Defense’s Threat Reduction Advisory Committee (TRAC), where he is Chair of the ChemBioWarfare Defense Panel. Dr. Scannon is inventor or co-inventor of several issued U.S. patents, ,and he has published numerous scientific abstracts and papers.

Dr. Jim Schaeffer joined Merck Research Laboratories (MRL) in 1986. During his first 16 years at MRL, he directed research groups focusing primarily on neuroendocrine-related projects. Jim joined the Department of External Scientific Affairs in 2003 with primary responsibility for all neuroscience licensing opportunities and during the next 18 months, he was directly involved in the signing of four major agreements. Jim moved to San Diego in 2004 to assume the role of Merck's "Science Scout" on the West Coast, with the responsibility to identify new opportunities across all therapeutic areas at all stages of development including enabling technologies. During the past four years, Jim has been directly involved in the execution of 7 major agreements with West Coast based organizations including recent agreements with AmbrX, Marcadia, MediVas, the Gladstone Institute, the University of California in San Francisco and the University of Texas-Southwestern. As of July 2008, Jim is also responsible for Merck's scouting efforts in China.

Dr. Randall Schatzman is currently President and CEO of Alder BioPharmaceuticals. Dr. Schatzman has successfully completed three rounds of venture funding totaling $67 million to support Alder’s therapeutic development activities. Dr. Schatzman and his scientific team have invented and patented two important technologies for the discovery and manufacture of monoclonal antibody therapeutics. Utilizing these technologies, they have progressed an antibody to the key pro-inflammatory cytokine IL-6 into the clinic for the treatment of rheumatoid arthritis and cancer in an industry-leading time of 20 months. This therapeutic was successfully partnered with Bristol Myers Squibb in a deal worth up to $1Bn. Additionally, they have created a development pipeline of products for important un-met medical needs in cancer, autoimmune and anemia of chronic disease.

Prior to co-founding Alder, Dr. Schatzman was Senior Vice President of Discovery Research at Celltech R&D Inc., where he led a group of 95 scientists responsible for aspects of the therapeutic antibody pipeline for Celltech. Prior to joining Celltech, he was Director of Gene Discovery at Mercator Genetics helping to solve the gene responsible for hereditary hemochromatosis and advancing the Del-1 angiogenesis factor into preclinical models while partnering Del-1 with Valentis. Prior to Mercator, he was at Syntex/Roche Bioscience where he helped found the Cancer and Developmental Biology Institute and served as Preclinical Team Leader for Cytovene and Team Leader for Valcyte, and was responsible for preclinical studies on Cellcept. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco.

Dr. Schmatz has over 30 years of drug discovery and development experience in pharmaceutical research. Most recently he was Vice President of Basic and Preclinical Research for Merck Research Laboratories in Japan where he was the Site Head for a research facility with over 400 researchers focused on Oncology and Metabolic Disorders. Previous to this role he was Vice President of Merck Basic Research in Rahway NJ where he was responsible for Human and Animal Infectious Disease Research and Immunology. During his 30 year career at Merck Dr. Schmatz has managed research teams across diverse therapeutic areas toward the successful delivery of pipeline compounds. Significant contributions include the discovery of; new biochemical pathways and drug targets, novel natural products with antimicrobial activity, and several approved drugs including CANCIDAS, an antifungal agent for treating serious life threatening hospital infections and INVANZ, an IV carbapenam antibiotic for treating bacterial infections. He has also served on, and chaired, a number of scientific committees for the World Health Organization. He is currently a member of the Board of Directors and Chairman of the External Scientific Advisory Committee for the Medicines for Malaria Venture in Geneva which is focused on developing new chemotherapeutic agents for treating malaria in the developing world. Dr. Schmatz has extensive experience in establishing research collaborations and developing licensing opportunities on an international level. He received his PhD in Biochemistry/Cell Biology from Rutgers University in 1984.

David Summa is currently the Chief Business Advisor of Acumen Pharmaceuticals, a pre-clinical drug development company that is developing the first effective therapeutics and diagnostics that prevent Alzheimer's disease.

Prior to joining Acumen, Dave was the President and CEO of Mendel Biotechnology, a successful genomics company that was the first to functionally characterize all the transcription factors in arabidopsis thaliana. Mendel's traits now form the core of the Monsanto product pipeline.

Before joining the ranks of Bay Area biotech entrepreneurs, Dave was a Vice President at Monsanto where he created Renessen, the joint venture between Cargill and Monsanto.

Prior to joining Monsanto, Dave was a partner at McKinsey & Company, Inc. where he was the global leader of the Innovation Practice. Dave received his BS and MS from MIT in the department of Chemical Engineering.

Mr. Tong works with his clients to understand how economic, financial, and reimbursement forces can be managed and how to influence product acceptance and utilization. His consulting engagements focus on strategic planning and implementation in early phases of product development, during clinical evaluation, and following regulatory approval. Mr. Tong has worked across a number of different clinical specialties and therapeutic categories including: hematology and oncology; solid organ and bone marrow transplantation; infectious diseases like HIV/AIDS and hepatitis; cardiovascular diagnostics and therapeutics; dermatology; orthopedic surgery; and anesthesiology/pain medicine.

Mr. Tong is an active member of numerous professional organizations and societies including: the Academy of Managed Care Pharmacy; American Public Health Association; American Society for Blood and Marrow Transplantation; American Society of Clinical Oncology; Infectious Disease Society of America; International Society for Heart and Lung Transplantation; International Society for Pharmacoeconomics and Outcomes Research; and Society for Investigative Dermatology.

Prior to founding Quorum Consulting, Mr. Tong was a senior associate with Corning HTA (now known as Covance), a Washington, DC health care consulting firm. Prior to entering the consulting field, Mr. Tong was active in clinical and health services research at the University of California at Los Angeles Neuropsychiatric Institute and the University of Pennsylvania Department of Medicine. He holds a MS Business and Management, Johns Hopkins University and a BA, University of Pennsylvania

Dr. Turner joined Merck Research Laboratories in 1985. Since then he has held many positions of increasing seniority at the company. In 1999 he was appointed Senior Vice President, Merck Frosst Centre for Therapeutic Research in Montreal, Canada. In 2002 he returned from Montreal to take up his current position as Senior Vice President, Worldwide Licensing and External Research. Dr. Turner oversees all of Merck's licensing activities and the management of academic relations. Through his multiple and diverse experiences in the Merck Research Laboratories, he has acquired a broad perspective on drug discovery and development. During Merv's tenure in Licensing, there has been a sizeable increase in deal activity for Merck, with over 230 significant transactions completed since 2003. Under Dr. Turner's leadership, Merck has also been active in mergers and acquisitions with companies such as Aton, Abmaxis, GlycoFi, Sirna and NovaCardia. Dr. Turner sees partnerships and M & A as a logical product of the cultural shift within Merck towards a more outward-facing and partner-friendly organization. Dr. Turner has authored over 80 articles in peer reviewed journals and has served on the editorial boards of many of them. Dr. Turner trained as a chemist at the University of Sheffield in the UK. After completing postdoctoral research at Harvard University, he returned to the UK and pursued an academic career in molecular parasitology until joining Merck in 1985.

Dr. Van Vlasselaer is the President and CEO of Arresto BioSciences. Before that, he was CEO of Avidia, a venture-financed biotechnology company, until it was sold to Amgen in October 2006. Prior to joining Avidia, he was Senior Vice President of Technical Operations at InterMune, Inc. (NASDAQ: ITMN) and Vice President of Product Development at Dendreon, Inc. (NASDAQ: DNDN). Before that, Peter was Staff Scientist at the Center for Nuclear Research in Mol, Belgium, where he managed research in Hematology, Immunology and Bone Biology. He was at DNAX Research Institute (Schering-Plough), where he conducted research in human B cell biology. Peter holds a B.S. in Zoology and a Ph.D. In Cellular Immunology from the University of Leuven, Belgium, and he was a Post-Doctoral Fellow at the Immunology and Rheumatology Division of the Stanford Medical School. He is inventor and author on multiple patents and publications in different fields, and was awarded the King Boudewijn Award for young entrepreneurs in Belgium.

Dr. Weisman is a member of the Johnson & Johnson Medical Devices & Diagnostics Group Operating Committee (GOC) and supports the GOC in steering its scientific and technical agenda, leading its investments and sponsoring its research and development agenda. Previously, Dr. Weisman was assistant professor of medicine at Johns Hopkins University School of Medicine.

Dr. Wiebe is Founder and President of Quantum Consulting based in Redwood City, California. His consulting practice is focused on biotechnology development, biosafety, manufacturing, quality assurance and GMP compliance. He has 24 years of experience in the CMC aspects of biotechnology and has participated as a member of numerous product development teams that were successful in bringing new biotech products through the development pipeline and into commercial life. He has held positions at the following companies: Genentech, 1984-1998 (Senior Scientist, Cell Culture Development; Sr. Director, Quality Control); BioReliance, 1998-2001 (Chief Scientific Officer and Vice President of Quality & Regulatory Affairs); IDEC Pharmaceuticals, 2001-2003 (Vice President of Quality); Biogen Idec, 2003-2005 (Vice President of Corporate Quality & Drug Compliance); Novartis (formerly Chiron), 2005-2007 (Vice President of Quality Assurance for U.S. Biopharmaceutical Operations). Earlier in his career Dr. Wiebe held positions at Duke University Medical School (Research Fellow), Cornell University Medical College (Assistant & Associate Professor), and the New York Blood Center (Associate Investigator). He received his Ph.D. in Microbiology from the University of Kansas and his B.S. in Natural Sciences from Sterling College (Kansas).

Barbara Yanni is Vice President and Chief Licensing Officer of Merck & Co., Inc. She leads the Corporate Licensing group which is responsible for negotiating agreements to acquire compounds, programs and new technologies to complement Merck's research programs and pipeline. Barbara works closely with her scientific and marketing colleagues at Merck to ensure that the company has access to discoveries that will enhance Merck?s ability to bring medicines to patients. Barbara and her team have played a major role in shaping a licensing strategy focused on building strong relationships with partners and potential partners. Merck's rapid, straightforward and clear dealmaking process has made the company an industry leader in the licensing arena. The result has been a significant increase in Merck's external relationships in recent years. In the past five years, Merck has executed approximately 250 significant licensing transactions in all stages, from technologies and early research collaborations to Phase III development candidates.

Before joining Corporate Licensing, Barbara was Executive Director of Corporate Development at Merck where she negotiated acquisitions, divestitures and other business arrangements. Barbara has also worked in other positions in Merck?s Finance area including Financial Evaluation and Analysis, Treasury and Tax. She joined Merck in 1985 as Domestic Tax Counsel after working as a tax lawyer for several years at Bristol-Myers and in private practice. Barbara graduated with an A.B. from Wellesley College and a J.D. from Stanford Law School. She also holds a Masters of Law in Taxation from New York University.